

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-24. (canceled)

25. (currently amended) A[[n]] substantially pure antibody that specifically binds to a polypeptide consisting of an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 1, 13, 21, 27, or 29, wherein the polypeptide functions as a transcriptional regulator and comprises a bromodomain.

26-28. (canceled)

29. (new) A substantially pure antibody that specifically binds to a polypeptide consisting of the amino acid sequence of any one of SEQ ID NOs: 1, 13, 21, 27, or 29.

30. (new) A substantially pure antibody that specifically binds to a polypeptide consisting of the amino acid sequence of any one of SEQ ID NOs: 1, 13, 21, 27, or 29, with up to 30 conservative amino acid substitutions, wherein the polypeptide regulates transcription of a gene and comprises a bromodomain.

31. (new) A substantially pure antibody that specifically binds to a polypeptide encoded by a nucleic acid that hybridizes under high stringency conditions (65 °C, 2x SSC) to a nucleotide sequence consisting of the complement of the coding sequence of any one of SEQ ID NOs: 2, 14, 22, 28, or 30, wherein the polypeptide regulates transcription of a gene and comprises a bromodomain.

32. (new) The antibody of claim 25, wherein the polypeptide comprises a C4HC3 zinc finger domain, a leucine zipper (LXXLL) domain, and a nuclear transport signal .

33. (new) The antibody of claim 30, wherein the polypeptide comprises a C4HC3 zinc finger domain, a leucine zipper (LXXLL) domain, and a nuclear transport signal.

34. (new) The antibody of claim 31, wherein the polypeptide comprises a C4HC3 zinc finger domain, a leucine zipper (LXXLL) domain, and a nuclear transport signal.

35. (new) The antibody of claim 25, wherein the antibody specifically binds to a polypeptide consisting of an amino acid sequence at least 95% identical to SEQ ID NO:1.

36. (new) The antibody of claim 25, wherein the antibody specifically binds to a polypeptide consisting of an amino acid sequence at least 95% identical to SEQ ID NO:13.

37. (new) The antibody of claim 25, wherein the antibody specifically binds to a polypeptide consisting of an amino acid sequence at least 95% identical to SEQ ID NO:21.

38. (new) The antibody of claim 25, wherein the antibody specifically binds to a polypeptide consisting of an amino acid sequence at least 95% identical to SEQ ID NO:27.

39. (new) The antibody of claim 25, wherein the antibody specifically binds to a polypeptide consisting of an amino acid sequence at least 95% identical to SEQ ID NO:29.

40. (new) The antibody of claim 29, wherein the antibody specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:1.

41. (new) The antibody of claim 29, wherein the antibody specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:13.

42. (new) The antibody of claim 29, wherein the antibody specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:21.

43. (new) The antibody of claim 29, wherein the antibody specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:27.

44. (new) The antibody of claim 29, wherein the antibody specifically binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO:29.